At the recent World Conference on Lung Cancer and European Society for Medical Oncology annual meetings, two packages of lung cancer data from a partnership between Akeso and Summit Therapeutics and another collaboration between iTeos Therapeutics and GSK showed much promise of disrupting the current standard of care. But they also drew some questions and debate. 

In this week's episode of “The Top Line,” Angus Liu from Fierce Pharma and Gabrielle Masson from Fierce Biotech discuss the key issues behind those two readouts.   

To learn more about the topic in this episode: 
iTeos-GSK's TIGIT combo shows 30% more tumor shrinkage than Jemperli, but safety signals scare investors
Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer
'Cooking with gas': Regeneron sees its Opdualag rival as next big thing for treating solid tumors
ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer field

At the recent World Conference on Lung Cancer and European Society for Medical Oncology annual meetings, two packages of lung cancer data from a partnership between Akeso and Summit Therapeutics and another collaboration between iTeos Therapeutics and GSK showed much promise of disrupting the current standard of care. But they also drew some questions and debate. 
In this week's episode of “The Top Line,” Angus Liu from Fierce Pharma and Gabrielle Masson from Fierce Biotech discuss the key issues behind those two readouts.   
To learn more about the topic in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/esmo-iteos-gsks-tigit-star-shows-30-more-tumor-shrinkage-jemperli-ph-2">iTeos-GSK's TIGIT combo shows 30% more tumor shrinkage than Jemperli, but safety signals scare investors</a></li>
<li><a href="https://www.fiercepharma.com/pharma/akeso-summit-pd-1-bispecific-crushes-merck-keytruda-new-standard-lung-cancer">Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/cooking-gas-regenerons-opdualag-rival-companys-next-big-thing-solid-tumor-treatments">'Cooking with gas': Regeneron sees its Opdualag rival as next big thing for treating solid tumors</a></li>
<li><a href="https://www.fiercepharma.com/pharma/bristol-myers-moves-opdualag-phase-3-trials-competitive-first-line-lung-cancer-field">ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer field</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement